- Home
- MYGN vs THRM Comparison
MYGN vs THRM Comparison
Compare MYGN & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- THRM
- Stock Information
- Founded
- MYGN 1991
- THRM 1991
- Country
- MYGN United States
- THRM United States
- Employees
- MYGN N/A
- THRM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- THRM Auto Parts:O.E.M.
- Sector
- MYGN Health Care
- THRM Consumer Discretionary
- Exchange
- MYGN Nasdaq
- THRM Nasdaq
- Market Cap
- MYGN 2.0B
- THRM 1.6B
- IPO Year
- MYGN 1995
- THRM 1993
- Fundamental
- Price
- MYGN $15.25
- THRM $42.33
- Analyst Decision
- MYGN Buy
- THRM Buy
- Analyst Count
- MYGN 12
- THRM 4
- Target Price
- MYGN $27.64
- THRM $57.00
- AVG Volume (30 Days)
- MYGN 990.7K
- THRM 253.3K
- Earning Date
- MYGN 11-07-2024
- THRM 10-30-2024
- Dividend Yield
- MYGN N/A
- THRM N/A
- EPS Growth
- MYGN N/A
- THRM 294.75
- EPS
- MYGN N/A
- THRM 2.13
- Revenue
- MYGN $823,600,000.00
- THRM $1,470,143,000.00
- Revenue This Year
- MYGN $13.85
- THRM $1.49
- Revenue Next Year
- MYGN $7.73
- THRM $5.84
- P/E Ratio
- MYGN N/A
- THRM $19.89
- Revenue Growth
- MYGN 12.15
- THRM 1.71
- 52 Week Low
- MYGN $15.18
- THRM $39.86
- 52 Week High
- MYGN $29.30
- THRM $62.93
- Technical
- Relative Strength Index (RSI)
- MYGN 16.18
- THRM 43.38
- Support Level
- MYGN $16.86
- THRM $43.28
- Resistance Level
- MYGN $19.60
- THRM $45.08
- Average True Range (ATR)
- MYGN 1.17
- THRM 1.36
- MACD
- MYGN -0.25
- THRM 0.14
- Stochastic Oscillator
- MYGN 0.90
- THRM 24.43
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.